Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (33 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 16 Nov 2006 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | DSP Midcap Fund |
|---|---|
| 16 Nov 2006 | ₹100.00 |
| 09 Jul 2008 | ₹94.92 |
| 03 Mar 2010 | ₹145.56 |
| 25 Oct 2011 | ₹136.08 |
| 18 Jun 2013 | ₹118.10 |
| 09 Feb 2015 | ₹211.67 |
| 03 Oct 2016 | ₹226.21 |
| 27 May 2018 | ₹227.32 |
| 18 Jan 2020 | ₹218.45 |
| 11 Sep 2021 | ₹266.32 |
| 05 May 2023 | ₹205.62 |
| 27 Dec 2024 | ₹320.18 |
| 20 Aug 2026 | ₹293.29 |
| Metric | DSP · Regular · IDCW NAV ₹30.15 Very High risk ★☆☆☆☆ | Category median Mid Cap Fund · 33 funds |
|---|---|---|
| -2.02% | +4.36% | |
| +6.73% | +14.16% | |
| +3.14% | +13.38% | |
| +3.06% | +7.79% | |
| +5.60% | +9.71% | |
| +4.95% | — | |
| +6.94% | +11.96% | |
| +5.81% | +10.86% | |
| +5.94% | +9.43% | |
| Risk | ||
| 17.74% | 17.59% | |
| 0.01 | 0.44 | |
| 0.02 | 0.61 | |
| -65.68% | -47.34% | |
| Nifty Midcap 150 | — | |
| -10.16% | -3.13% | |
| 1.05 | 0.97 | |
| 84.8% | 91.4% | |
| 130.5% | 102.1% | |
| 1.73% | 2.04% | |
| ₹19,539Cr | ₹9,315Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 9% | 41% | |
| Vinit Sambre | — | |
| 16 Nov 2006 | — | |
| 63 | — | |
| 27.2% | — | |
| 4.3% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.